ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF) (2020 - 2026)
ARS Pharmaceuticals (SPRY) reported Depreciation & Amortization (CF) of $397000.0 for Q1 2026, up 41.79% on a YoY basis from $280000.0 in Q1 2025, and down 4.8% sequentially from $417000.0 in Q4 2025.
ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $397000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 41.79% year-over-year to $397000.0; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 247.54% YoY), and the FY2025 full-year result was $1.4 million, up 1630.38% from the prior year.
- Depreciation & Amortization (CF) slipped to $397000.0 in Q1 2026, from $417000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $417000.0 in Q4 2025 to a low of -$37000.0 in Q2 2022.
- A 5-year average of $140812.5 and a median of $64500.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) tumbled 117.7% in 2022 and soared 2445.45% in 2025, its largest moves.
- Tracing SPRY's Depreciation & Amortization (CF) over 5 years: stood at $14000.0 in 2022, then jumped by 614.29% to $100000.0 in 2023, then plunged by 71.0% to $29000.0 in 2024, then soared by 1337.93% to $417000.0 in 2025, then decreased by 4.8% to $397000.0 in 2026.
- Business Quant data shows SPRY's Depreciation & Amortization (CF) at $397000.0 in Q1 2026, $417000.0 in Q4 2025, and $391000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | 397,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 397,000.00 |
| Mar 31, 2026 | 397,000.00 |
| Dec 31, 2025 | 417,000.00 |
| Dec 31, 2025 | 417,000.00 |
| Sep 30, 2025 | 391,000.00 |
| Sep 30, 2025 | 391,000.00 |
| Jun 30, 2025 | 279,000.00 |
| Jun 30, 2025 | 279,000.00 |
| Mar 31, 2025 | 280,000.00 |
| Mar 31, 2025 | 280,000.00 |
| Dec 31, 2024 | 29,000.00 |
| Dec 31, 2024 | 29,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |